Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

Merck Sharp & Dohme LLC · NCT06623409

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–45 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
124
US sites recruiting
2
Study start
November 12, 2024
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later.

A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it.

Being studied: GARDASIL®9 (G9); V540B

Conditions: Healthy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health based on medical history, physical examination, vital sign (VS) measurements and electrocardiograms (ECGs) performed before randomization.

Exclusion Criteria

The key exclusion criteria include but are not limited to the following:

  • Has a history of abnormal Pap smears, HPV- related external genital lesions (eg,condyloma acuminate, vulval intraepithelial neoplasia (VIN), or prostatic intraepithelial neoplasia (PIN)) or external genital cancer (eg, penile cancer), HPV-related vaginal or anal lesions (eg, condyloma acuminata or vaginal intraepithelial neoplasia (VaIN)) or vaginal or anal cancer.
  • Has a history of cancer (malignancy).
  • Has received any HPV vaccine or is expected to receive any HPV vaccine during the study, outside the protocol.

Recruiting US locations

  • Velocity Clinical Research, Hallandale Beach ( Site 0003)

    Hallandale, FL 33009

    Site contact: Study Coordinator · 954-455-5757

  • Research Centers of America ( Hollywood ) ( Site 0001)

    Hollywood, FL 33024

    Site contact: Study Coordinator · 954-324-4706

Study contacts (from the official record)

  • Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
All healthy volunteers studies in Florida →
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). (NCT06623409) | Bored Studies